Search

Your search keyword '"Lederer, David J"' showing total 965 results

Search Constraints

Start Over You searched for: Author "Lederer, David J" Remove constraint Author: "Lederer, David J"
Sorry, I don't understand your search. ×
965 results on '"Lederer, David J"'

Search Results

251. Plasma Monocyte Chemotactic Protein-1 (MCP-1) Levels at 24 hours are a Biomarker of Primary Graft Dysfunction Following Lung Transplantation

252. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation

253. Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT

254. Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension

255. ACQUIRED METHEMOGLOBINEMIA IS UNDER-RECOGNIZED IN THE SERIOUSLY CRITICALLY ILL

256. A comparison of visual and quantitative methods to identify interstitial lung abnormalities

258. Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY

259. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis

261. Interleukin-6 and Tumor Necrosis Factor-α Are Associated with Quality of Life–Related Symptoms in Pulmonary Arterial Hypertension

262. A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

263. Genome-wide association analysis identifies six new loci associated with forced vital capacity

264. Body composition and mortality after adult lung transplantation in the United States.

265. Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.

266. Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation

268. A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

269. Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies.

270. Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.

271. Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation.

272. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

273. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

275. Body Composition and Mortality after Adult Lung Transplantation in the United States

278. Genome-wide association analysis identifies six new loci associated with forced vital capacity

279. Plasma Complement Levels Are Associated with Primary Graft Dysfunction and Mortality after Lung Transplantation

280. The feasibility of measuring frailty to predict disability and mortality in older medical intensive care unit survivors

281. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

283. Clinical risk factors for primary graft dysfunction after lung transplantation.

284. Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.

285. Frailty phenotypes and mortality after lung transplantation: A prospective cohort study

287. A novel patient‐centered “intention‐to‐treat” metric of U.S. lung transplant center performance

289. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.

290. Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation.

291. Endothelial repair capacity and apoptosis are inversely related in obstructive sleep apnea

292. Efficacy of Dupilumab in Patients with Moderate-to-Severe Asthma and Persistent Airflow Obstruction.

294. High Burden of Palliative Needs among Older Intensive Care Unit Survivors Transferred to Post–Acute Care Facilities. A Single-Center Study

295. Latent Class Analysis Identifies Distinct Phenotypes of Primary Graft Dysfunction After Lung Transplantation

296. Preoperative Serum Albumin Levels Predict 1-Year Postoperative Survival of Patients Undergoing Heart Transplantation

300. Primary graft dysfunction: Long-term physical function outcomes among lung transplant recipients.

Catalog

Books, media, physical & digital resources